TF
Schedule 13G filing
Tetragon Financial Management LP disclosed a 5.3% stake in Silence Therapeutics plc (SLN)
Tetragon Financial Management LP reported owning 5.3% of Silence Therapeutics plc (SLN) (9,878,565 shares) in a Schedule 13G filed Oct 13, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 13, 2026
- Source
- Schedule 13G
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.